Dohee Kwon1, Sehui Kim1, Pil-Jong Kim2, Heounjeong Go3, Soo Jeong Nam4,5, Jin Ho Paik6, Young A Kim7, Tae Min Kim8, Dae Seog Heo8, Chul Woo Kim1,5,9, Yoon Kyung Jeon1,5,9. 1. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. 2. Biomedical Knowledge Engineering Laboratory, Seoul National University School of Dentistry, Seoul, South Korea. 3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 4. Department of Pathology, Korea Cancer Center Hospital, Seoul, South Korea. 5. The Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, South Korea. 6. Department of Pathology, Seoul National University Bundang Hospital, Seongnam-si, South Korea. 7. Department of Pathology, Seoul Metropolitan Government Boramae Hospital, Seoul, South Korea. 8. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. 9. Tumor Microenvironment Global Core Research Center, Seoul National University, Seoul, South Korea.
Abstract
AIMS: To investigate the clinicopathological characteristics of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expression in the tumour microenvironments of diffuse large B cell lymphoma (DLBCL). METHODS AND RESULTS: Tumour tissues from 126 DLBCL patients were immunostained for PD-L1 and PD-1. The expression of PD-L1 by tumour cells and/or tumour-infiltrating immune cells (mainly macrophages) was evaluated, and the number of tumour-infiltrating PD-1(+) cells was assessed. PD-L1 expression in tumour cells was observed in 61.1% of DLBCLs, with a weak intensity in 29.4%, moderate intensity in 21.4% and strong intensity in 10.3% of cases. Strong PD-L1 expression in tumour cells was associated significantly with the presence of B symptoms (adjusted P = 0.005) and Epstein-Barr virus (EBV) infection (adjusted P = 0.015), and tended to be higher in activated B cell-like immunophenotype (16.7%) than germinal centre B cell-like immunophenotype (2.5%) (adjusted P = 0.271). DLBCLs with PD-L1 expression in tumour cells/macrophages showed similar clinicopathological characteristics. The quantity of PD-1(+) tumour-infiltrating lymphocytes correlated positively with the level of PD-L1 expression in tumour cells (P = 0.042) or in tumour cells/macrophages (P = 0.03). Increased infiltration of PD-1(+) cells was associated with prolonged progression-free survival (P = 0.005) and overall survival (P = 0.026) in DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), whereas PD-L1 expression had no prognostic significance. CONCLUSIONS: PD-L1 and PD-1 were expressed variably in DLBCLs by tumour cells and tumour-infiltrating immune cells and might be potential therapeutic targets using PD-1/PD-L1 blockade.
AIMS: To investigate the clinicopathological characteristics of programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) expression in the tumour microenvironments of diffuse large B cell lymphoma (DLBCL). METHODS AND RESULTS:Tumour tissues from 126 DLBCL patients were immunostained for PD-L1 and PD-1. The expression of PD-L1 by tumour cells and/or tumour-infiltrating immune cells (mainly macrophages) was evaluated, and the number of tumour-infiltrating PD-1(+) cells was assessed. PD-L1 expression in tumour cells was observed in 61.1% of DLBCLs, with a weak intensity in 29.4%, moderate intensity in 21.4% and strong intensity in 10.3% of cases. Strong PD-L1 expression in tumour cells was associated significantly with the presence of B symptoms (adjusted P = 0.005) and Epstein-Barr virus (EBV) infection (adjusted P = 0.015), and tended to be higher in activated B cell-like immunophenotype (16.7%) than germinal centre B cell-like immunophenotype (2.5%) (adjusted P = 0.271). DLBCLs with PD-L1 expression in tumour cells/macrophages showed similar clinicopathological characteristics. The quantity of PD-1(+) tumour-infiltrating lymphocytes correlated positively with the level of PD-L1 expression in tumour cells (P = 0.042) or in tumour cells/macrophages (P = 0.03). Increased infiltration of PD-1(+) cells was associated with prolonged progression-free survival (P = 0.005) and overall survival (P = 0.026) in DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), whereas PD-L1 expression had no prognostic significance. CONCLUSIONS:PD-L1 and PD-1 were expressed variably in DLBCLs by tumour cells and tumour-infiltrating immune cells and might be potential therapeutic targets using PD-1/PD-L1 blockade.
Authors: Janice S Ahn; Ali Al-Habib; Jeffrey A Vos; Aliyah R Sohani; Oralia Barboza-Quintana; Juan P Flores; Sijin Wen; Flavia G Rosado Journal: Ann Clin Lab Sci Date: 2020-03 Impact factor: 1.256
Authors: Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa Journal: Blood Date: 2019-04-11 Impact factor: 22.113
Authors: Daniel J Landsburg; Alexa Koike; Sunita D Nasta; Jakub Svoboda; Stephen J Schuster; Mariusz A Wasik; Gabriel C Caponetti Journal: Cancer Immunol Immunother Date: 2020-08-28 Impact factor: 6.968
Authors: Yasodha Natkunam; Dita Gratzinger; Amy Chadburn; John R Goodlad; John K C Chan; Jonathan Said; Elaine S Jaffe; Daphne de Jong Journal: Blood Date: 2018-08-06 Impact factor: 22.113